Evidence map›Paper›PMID 31279729›Full record

ReviewAdvanced drug delivery reviews2019

Integrating nanomedicine into clinical radiotherapy regimens.

Allison N DuRoss, Megan J Neufeld, Shushan Rana, Charles R Thomas, Conroy Sun

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Allison N DuRossDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA.
Megan J NeufeldDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA.
Shushan RanaDepartment of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
Charles R ThomasDepartment of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
Conroy SunDepartment of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA; Department of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: sunc@ohsu.edu.

Funding

Synergistic combination of nanotechnology and radiation in medicineR35GM119839 · NIGMS · OREGON STATE UNIVERSITY · PI SUN, CONROY GHIN CHEE · 2016 to 2020
$1.8M
NIGMS NIH HHS R35 GM119839
6 · The paper itself

Abstract

While the advancement of clinical radiotherapy was driven by technological innovations throughout the 20th century, continued improvement relies on rational combination therapies derived from biological insights. In this review, we highlight the importance of combination radiotherapy in the era of precision medicine. Specifically, we survey and summarize the areas of research where improved understanding in cancer biology will propel the field of radiotherapy forward by allowing integration of novel nanotechnology-based treatments.

Indexed as

NanomedicineAnimalsCombined Modality TherapyHumansImmunotherapyNeoplasmsCancerChemoradiotherapyDosingDrug deliveryMultimodal therapyNanoparticlesRadiation therapy

Identifiers

PMID31279729
PMCPMC6745263

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.